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Abstract Resistance to third-generation cephalosporins in
Gram-negative bacteria is emerging inAsia.We report the prev-
alence and distribution of extended-spectrum beta-lactamase
(ESBL), AmpC beta-lactamase and carbapenemase-coding
genes in cefotaxime-resistant Enterobacteriaceae isolates from
bloodst ream infec t ions (BSI) in Cambodia . Al l
Enterobacteriaceae isolated from BSI in adult patients at
Sihanouk Hospital Centre of HOPE, Phnom Penh, Cambodia
(2007–2010) were assessed. Antimicrobial susceptibility test-
ing was carried out by disc diffusion and MicroScan according
to Clinical and Laboratory Standards Institute (CLSI) guide-
lines. Screening for ESBL, plasmidic AmpC and
carbapenemase-coding genes was performed by multiplex
polymerase chain reaction (PCR) sequencing assays.
Identification of the ST131 clone was performed in all CTX-
M-positive Escherichia coli, using PCR targeting the papB
gene. Out of 183 Enterobacteriaceae, 91 (49.7 %) isolates (84
BSI episodes) were cefotaxime-resistant: E. coli (n=68),
Klebsiella pneumoniae (n=17) and Enterobacter spp. (n=6).
Most episodes were community-acquired (66/84; 78.3 %).
ESBLs were present in 89/91 (97.8 %) cefotaxime-resistant
isolates: 86 (96.6 %) were CTX-M, mainly CTX-M-15 (n=
41) and CTX-M-14 (n=21). CTX-M of group 1 were frequent-
ly associated with TEM and/or OXA-1/30 coding genes and
with phenotypic combined resistance to ciprofloxacin,
sulphamethoxazole–trimethoprim and gentamicin (39/50,
78.0 %). Plasmidic AmpC (CMY-2 and DHA-1 types) were
found alone (n=2) or in combination with ESBL (n=4).
Eighteen E. coli isolates were identified as B2-ST131-O25B:
11 (61.1 %) carried CTX-M-14. No carbapenemase-coding
genes were detected. ESBL among Enterobacteriaceae from
BSI in Cambodia is common, mainly associated with CTX-
M-15 and CTX-M-14. These findings warrant urgent action
for the containment of antibiotic resistance in Cambodia.
Introduction
Resistance to third-generation cephalosporins in Gram-
negative bacteria has been associated with increased
healthcare costs and higher rates of inappropriate therapy
and mortality [1, 2]. The predominant underlying mechanism
is the presence of plasmid-mediated extended-spectrum beta-
lactamase (ESBL), mainly of the CTX-M, SHVor TEM types.
Over the past decade, CTX-M has become the most prevalent
ESBL type worldwide [3].
High rates of ESBL positivity among Escherichia coli,
Klebsiella species and other Enterobacteriaceae have been
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described across Asia, in both hospital as well as community
settings [4]. CTX-M, particularly CTX-M-15 and CTX-M-14.
have been reported as the most common ESBL types in the
Indian subcontinent, Southeast and East Asia, although pat-
terns may differ locally [5]. Common risk factors for the ac-
quisition of ESBL-producing strains in Southeast Asia include
previous exposure to antibiotics (particularly cephalosporins
and fluoroquinolones) and recent (i.e. <3 months) or actual
hospitalisation [6, 7].
For Cambodia, data on prevalence, types and mechanisms
of ESBL are very scarce. In a prospective cohort study of 93
patients with urinary tract infection, Ruppé and coworkers
reported the presence of ESBL (all of the CTX-M type) in
37.7 % of E. coli from urine [8].
In a recent study in Cambodian hospitalised adults, we
described the predominance of Gram-negative bacteria (most-
ly E. coli) in bloodstream infections (BSI), with a high resis-
tance rate (50 %) to third-generation cephalosporins in
Enterobacteriaceae and frequent association of co-resistance
to fluoroquinolones, sulphamethoxazole–trimethoprim
(SMX-TMP) and gentamicin [9]. Here, we report the mecha-
nisms underlying these complex resistance patterns in




Sihanouk Hospital Centre of HOPE (SHCH) is a 40-bed non-
governmental organisation (NGO) hospital for adults in
Phnom Penh, Cambodia. It provides free care for the poor,
with specific focus on patients with the human immunodefi-
ciency virus (HIV) and the chronically ill. Microbiological
facilities were installed in 2005, along with a local capacity-
building programme focusing on the diagnosis and manage-
ment of infectious diseases at the hospital level. In July 2007,
a prospective study was started in patients presenting with
presumed BSI.
Between 2007 and 2010, blood cultures with registration of
demographic and clinical data were systematically obtained
for all adult patients presenting with signs of systemic inflam-
matory response syndrome (SIRS) [10]. Venous blood (2 × 10
ml) was cultured in homemade brain heart infusion broth bot-
tles (Bio-Rad, Berkeley, CA, USA) (July 2007–March 2009)
and from April 2009 onwards in BacT/ALERT culture bottles
(bioMérieux, Marcy l’Etoile, France). Blood cultures were
incubated for 7 days at 35 °C and were monitored daily for
growth. As part of standard patient care, isolates were identi-
fied by conventional biochemical tests and assessed for anti-
biotic susceptibility by disc diffusion. Isolates were stored at
−70 °C on porous beads in cryopreservative (Microbank, Pro-
Lab Diagnostics, Richmond Hill, Canada), and were shipped
in batches to the Institute of Tropical Medicine (ITM),
Antwerp (September 2010 and January 2011), where identifi-
cation and susceptibility testing were verified with MicroScan
(Siemens, Germany) according to Clinical and Laboratory
Standards Institute (CLSI) guidelines (M100-S22) [11].
Isolates displaying intermediate susceptibility were consid-
ered resistant. All cefotaxime-resistant isolates from this col-
lection were then referred to the National Reference
Laboratory (Centre Hospitalier Universitaire Dinant-
Godinne UCL) for confirmation of ESBL expression and ge-
notypic characterisation of the isolates.
Screening for genes encoding conventional ESBL (CTX-
M of groups 1, 2 and 9, SHV, TEM), minor ESBL (VEB,
PER, BEL, GES), pAmpC and carbapenemase (VIM, IMP,
NDM, OXA-48, KPC) was done by an end-point multiplex
polymerase chain reaction (PCR) assay using a set of four
validated (ISO 15189 standard) assays [12, 13], followed by
sequencing of all the CTX-M genes detected. Sequence ho-
mology was determined by the BLASTX search tool using a
non-redundant protein sequences’ database and comparison
with the Lahey database (http://www.lahey.org/studies/).
Identification of the ST131 clone was performed in CTX-
M-positive E. coli, using PCR targeting the papB gene [14].
Clinical data and definitions
Basic clinical and epidemiological data were collected in all
patients during the study through the laboratory request form.
Infections were considered ‘nosocomial’ if they occurred
more than two days after hospitalisation and ‘community-ac-
quired’ if starting before or during the two first days of
hospitalisation.
Statistical analysis
Differences in proportions were assessed using Fisher’s exact
test and considered statistically significant at p-values<0.05.
Data were analysed using Stata version 10.2 (StataCorp,
College Station, TX, USA) and Excel 2003 (Microsoft
Corporation, Redmond, WA, USA).
Ethical considerations
Ethical approval was granted from the review boards at the
Institute of Tropical Medicine, Antwerp, the University
Hospital Antwerp and the National Ethics Committee for
Health Research, Phnom Penh, Cambodia. Patients were iden-
tified with a unique hospital number (code known by the prin-
ciple investigator), while the anonymity status of the patients
to any third party was preserved and guaranteed during and
after the study.
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Results
Clinical and demographic data
Out of 183 non-duplicate Enterobacteriaceae isolates from
blood cultures, 91 isolates (from 84 BSI episodes in 83 pa-
tients) were cefotaxime-resistant. These included E. coli (n=
68), K. pneumoniae (n=17), Enterobacter cloacae (n=5) and
E. kobei (n=1). Seven patients had a polymicrobial BSI with
two different Enterobacteriaceae isolated.
Among the 83 patients infected with cefotaxime-resistant
isolates, 59.0 % were women, with a median age of 47 years
(range 17–78 years); they came from 14 different provinces of
Cambodia, predominantly the capital region and adjacent
southeastern provinces. The main associated co-morbidities
were infection with HIV (n=20; 24.1%), chronic liver disease
(n=18; 21.7 %), chronic renal disease (n=12; 14.5 %) and
diabetes mellitus (n=13; 15.7 %).
The primary sources of infection could be clearly identified
in 56 out of 84 episodes (66.7 %), and were mainly urogenital
(n=29; 51.8 %) and intra-abdominal infections (n=18;
32.1 %), besides respiratory tract infections (n=5; 8.9 %)
and skin and soft tissue infections (n=4; 7.1 %).
Phenotypic resistance patterns
Co-resistance to non-beta-lactam antibiotics was frequently
found, in particular for ciprofloxacin, SMX-TMP and genta-
micin. For instance, the respective resistance rates for these
antibiotics in E. coli were 92.6 % (63/68), 95.6 % (65/68) and
76.5 % (52/68). Combined resistance to these three antibiotics
in addition to cefotaxime resistance occurred overall in 61.5%
(56/91) of the isolates and was particularly frequent in E. coli
(88.2 %; 60/68). In contrast, we did not observe resistance to
meropenem and amikacin, and found low levels of resistance
to colistin (4/91 (4.4%). Of note, colistin resistance was found
in 3 out of 6 Enterobacter spp. isolates.
Resistance mechanisms
ESBL with a unique acquired resistance mechanism to
extended-spectrum third-generation cephalosporins (or to cef-
otaxime) was found in 85 of 91 (93.4 %) isolates, plasmidic
AmpC (pAmpC) in 2 of 91 (2.2 %) and a combination of
ESBL and pAmpC in 4 out of 91 (4.4 %). In line with the
phenotypic findings, no carbapenemase-coding genes were
present in any of the isolates.
The distribution frequency of the different ESBLs, CTX-M
groups and gene variants is shown in Table 1. blaCTX-M, pres-
ent in 86 of 88 ESBL-positive isolates (97.7 %), was by far the
most common resistance encoding gene. Most CTX-M types
belonged to CTX-M-1 group (n=50) or to CTX-M-9 group
(n=30); six isolates harboured a combination of genes from
CTX-M- group 1 and CTX-M group 9. CTX-M-15 (n=41)
and CTX-M-14 (n=21) were the most common types.
Plasmidic AmpC included CMY-2-like in four E. coli and
DHA-1 in two K. pneumoniae isolates, respectively. During
the study period, the annual proportion of CTX-M among
Enterobacteriaceae fluctuated around an average of 47.0 %
(86/183), without a significant trend throughout the years (da-
ta not shown).
The association of genes encoding for various other non-
ESBL beta-lactamase (i.e. blaTEM, blaSHVor blaoxa-1/-30) was
frequent. Of note, the presence of OXA-1/-30 was found in 35
of 46 isolates (76.1 %) with CTX-M-15. Co-resistance to the
non-beta-lactam antibiotics (i.e. ciprofloxacin, SMX-TMP
and gentamicin) was found more frequently in isolates with
CTX-M-1 group (39/50; 78.0 %) as compared to those posi-
tive for CTX-M-9 group 9 (14/30; 46.7 %, p=0.007).
No significant differences in antibiotic exposure or noso-
comial infection rates was observed between patients with
isolates carrying CTX-M-1 versus CTX-M-9 group (data not
shown).
Presence of E. coli ST131
Out of 67 CTX-M-positive E. coli tested, 18 (26.9 %) were
found to be of the B2-ST131-O25B type. Figure 1 displays the
evolution of its proportion over time, with a gradual absolute
and proportional increase of E. coli ST131 being observed
over time. Of note, isolates of the ST131 type were more
closely associated with CTX-M-9 group (15/18, 83.3 %) as
compared to 10 out of 49 (20.4 %) non-ST131 E. coli,
p<0.001); this was particularly the case for CTX-M-14 (11
out of 18 E. coli ST131; 61.1 %). By contrast, CTX-M-1
group genes were significantly more frequent among non-
ST131 E. coli isolates [36/49 (73.5 %) versus 3/18 (16.7 %)
in ST131 E. coli isolates, p<0.001].
Besides these associations, infections caused by E. coli of
the B2-ST131-O25B type were not significantly different
from those caused by non-ST131 E. coli in terms of patients’
age, gender, co-morbidity and co-resistance to non-beta-
lactam antibiotics (Table 2).
Discussion and conclusion
In this study, we found that resistance to third-generation
cephalosporins among Enterobacteriaceae was widespread in
Cambodia and was mostly associated with CTX-M type
ESBLs, either alone or in combination with other beta-
lactamases, occasionally including pAmpC (i.e. CMY-2-like
type inE. coli and DHA type inK. pneumoniae).We observed
a clear predominance of CTX-M-15 and of CTX-M-14, but
also a wide variety of genetic patterns, including combinations
of two different CTX-M types. The presence of an ESBL was
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very often associated with co-resistance to ciprofloxacin,
SMX-TMP and gentamicin, especially in isolates of CTX-
M-15 type.
The overall findings are in line with data from other Asian
countries [4]. A surveillance study of 699 invasive
Enterobacteriaceae from 11 countries in the Asian-Pacific re-
gion [15] and other studies confirmed the high prevalence
rates of CTX-M in the region, with predominance of CTX-
M-15 on the Indian subcontinent [16], Singapore, Malaysia
and the Philippines [17], whereas CTX-M-14 was most fre-
quently found in China [18], South Korea [19] and Taiwan
[20]. The presence of non-ESBL mechanisms, e.g. pAmpC
(CMY, DHA), also frequently occurs in India, Taiwan,
South Korea and Vietnam [15].
Over the years of the study, we also noticed a fast emer-
gence of the ST131 E. coli clone and its close association with
CTX-M-14. This is in contrast with several reports on the
globally emerging, multidrug-resistant CTX-M-15-positive
Table 1 Resistance mechanisms underlying cefotaxime resistance in 91 Enterobacteriaceae isolates from bloodstream infections (BSI), Cambodia
ESBL (n=88) TEM SHV OXA-1/30 No. of
isolates
+ pAmpC CipSMXGef E. coli
ST131
CTX-M-1 group (n=50)1
CTX-M-15 (n=41) − − + 18 1 (CMY-2-like) 15 2
+ − − 6 − 3 −
+ − + 9 − 8 1
+ + + 5 − 4 −
− − − 2 1 (CMY-2-like) 0 −
+ + − 1 − 1 −
CTX-M-55 (n=7) + − − 6 1 (CMY-2-like) 5 −
− − − 1 − 1 −
CTX-M-3 (n=2) + − − 1 − 1 −
+ + − 1 − 0 −
CTX-M-9 group (n=30)b
CTX-M-14 (n=21) + − − 8 − 6 4
− − − 8 − 5 7
+ + − 3 − 0 −
− + − 1 − 0 −
− − + 1 − 0 −
CTX-M-27 (n=9) + − − 4 − 2 1
− − − 4 − 1 3
+ + − 1 − 0 −
CTX-M-1+M-9 group (n=6)c
CTX-M-15+CTX-M-14 (n=2) + + − 1 1 (DHA) 1 −
− − + 1 − 0 −
CTX-M-15+CTX-M-27 (n=3) − − + 1 − 1 −
− − − 1 − 0 −
+ − + 1 − 1 −
CTX-M-3+CTX-M-27 (n=1) + + − 1 − 0 −
Non-CTX-M ESBL (n=2)d + + − 1 − 0 −
− + − 1 − 0 −
Non-ESBL (n=3)e + − − 1 1 (CMY-2-like) 0 −
+ + + 1 1 (DHA) 0 −
+ + − 1 − 0 −
a Includes E. coli (n=39), K. pneumoniae (n=6) and Enterobacter spp. (n=5)
b Includes E. coli (n=25) and K. pneumoniae (n=5)
c Includes E. coli (n=3) and K. pneumoniae (n=2) and Enterobacter spp. (n=1)
d Includes K. pneumoniae (n=3)
e Includes E. coli (n=1) and K. pneumoniae (n=1)
fCipSMXGe combined resistance to cefotaxime, ciprofloxacin (Cip), SMX-TMP (SMX) and gentamicin (Ge)
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ST131 E. coli [3, 21, 22]. However, recent data from Japan
also reported the association of the ST131 clone with CTX-M-
14 [23]. In China, E. coli ST131was found in association with
either CTX-M-14 and CTX-M-15 [18], whereas in
neighbouring Laos, E. coli ST131 associated with CTX-M-
14 is quickly emerging, along with other sequence types, such
as ST648 and ST405 [24]. Together with these recent publi-
cations, our findings may help to refine the picture of E. coli
ST131 in Asia, of which the knowledge is still limited [25], its
recent epidemiology being probably the result of the vertical
(clonal) spread of successful clones and horizontal spread of
resistance genes through plasmid transfers within and across
different species [26]. Subsequent shuffling and recombina-
tion of genes in the same or in different plasmids could explain
diversification over time. Also, these findings from invasive
isolates are but the tip of the iceberg and a better understand-
ing of the entire E. coli epidemiology will require more data
on the presence of ST131 in other patient groups, healthy
carriers, pet and food animals, and the environment at large.
Finally, in spite of the earlier described association of the
ST131 clone with increased clinical severity [3], we found no
evidence for this among our patients. The lack of difference in
the clinical outcome of infections caused by ST131 E. coli has
recently been described in a patient series fromSouthKorea [27].
However, the clinical correlate of in vitro observed virulence
factors in E. coli infections may be very complex [28] and the
assessment of their clinical impact requires probably large num-
bers ofmore refined patient datawith sufficiently long follow-up.
Our study had several limitations. The number of isolates
was limited and collected at a single centre over a relatively
short period; this may limit their generalisability. Long-term
surveillance from multiple sites in Cambodia is needed in
order to confirm the trends we observed in our study. Next,
given the high rates of comorbidity and of prior antibiotic use
in our study population, our results may have overestimated
the resistance rates in the community; the rough distinction
between ‘community-acquired’ and ‘nosocomial’ isolates did
not allow in-depth analysis of these findings. Finally, com-
plete clinical information could not be found for all patients;
prospective clinical studies in parallel with surveillance stud-
ies are needed in order to assess the clinical context and impact
of the newly observed resistance patterns.
Nevertheless, these data represent—to the best of our
knowledge—the first detailed description in Cambodia of re-
sis tance mechanisms in systemat ical ly collected
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Fig. 1 Prevalence of extended-spectrum beta-lactamase (ESBL)
Escherichia coli ST131 over time (x-axis displays calendar years, y-axis
absolute number of different groups of E. coli isolates
Table 2 Characteristics of patients infected with CTX-M-positive ST131 E. coli as compared to CTX-M-positive non-ST131 E. coli
Infection with E. coli ST131 Infection with E. coli non-ST131 p-Value
n=18 % n=49 %
Female gender 13 72.2 28 57.1 0.397
Age>50 years 7 38.9 23 46.9 0.592
Infection occurred in year 2010 12 66.7 21 42.9 0.104
Infection occurred during wet seasona 14 77.8 30 61.2 0.255
Nosocomial infection 3 16.7 7 14.3 1.000
Infection with urologic focus 8 44.4 21 42.9 1.000
Diedb 6 33.3 13 26.5 0.760
Infected with isolate carrying CTX-M-15 3 16.7 32 65.3 <0.001
Infected with isolate carrying CTX-M-14 11 61.1 6 12.2 <0.001
Underlying diabetes mellitus 2 11.1 10 20.4 0.490
Underlying HIV-infectionc 3 16.7 10 20.4 1.000
Underlying chronic liver disease 3 16.7 14 28.6 0.527
aWet season: June–November
b Outcome assessed at hospital discharge
cHIV human immunodeficiency virus
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At a larger scale, our findings highlight the urgent need for
an implementation of a nationwide surveillance system in
Cambodia [29], whereby particular attention should be given
to community-acquired and nosocomial infections alike. The
recent introduction of blood culture facilities and laboratory
capacity-building in several provincial and public hospitals
may constitute a first step towards the creation of a network
of skilled laboratories, which may then be able to conduct
bacterial surveillance studies [29].
The observed complex combinations of resistance genes
suggest intense antibiotic pressure, as confirmed by the high
rates of reported prior antibiotic use. This also highlights an
urgent need for the global surveillance of antibiotic usage in
humans and animals in Cambodia [30], in order to curb the
further increase of resistance.
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